[{"id":"d44ae7ac-0c9e-44e0-9485-99103e6996fd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04228406","created_at":"2021-01-18T20:34:28.306Z","updated_at":"2024-07-02T16:36:51.354Z","phase":"Phase 1","brief_title":"Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy Evaluation of GST-HG161","source_id_and_acronym":"NCT04228406","lead_sponsor":"Fujian Cosunter Pharmaceutical Co. Ltd","biomarkers":" MET","pipe":" | ","alterations":" MET amplification • MET expression • MET positive","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET expression • MET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemnelatinib (GST-HG161)"],"overall_status":"Unknown status","enrollment":" Enrollment 62","initiation":"Initiation: 07/01/2019","start_date":" 07/01/2019","primary_txt":" Primary completion: 09/30/2020","primary_completion_date":" 09/30/2020","study_txt":" Completion: 12/31/2020","study_completion_date":" 12/31/2020","last_update_posted":"2020-01-14"}]